ArticleOncoimmunology
A cell-engineered system to assess tumor cell sensitivity to CD8
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- PD-1 regulates latent effector differentiation of thymic cytotoxic CD8Nature communications · 2026Article
- Measurement of T Cell Migration by T Cell-Dependent Bispecific Antibody in Cancer Cells and T Cell Cross-Linking.Methods in molecular biology (Clifton, N.J.) · 2026Article
- DCAF13 Regulates Cell Proliferation and Immune Escape of Hepatocellular Carcinoma Through Activating the NF-κB Pathway.Cell biochemistry and biophysics · 2025Article
- Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.Nature protocols · 2024Review
- Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8Science advances · 2024Article
- TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells.Frontiers in immunology · 2024Article
- Article
- Activated T cell therapy targeting glioblastoma cancer stem cells.Scientific reports · 2023Article
- Ribonuclease 1 Enhances Antitumor Immunity against Breast Cancer by Boosting T cell Activation.International journal of biological sciences · 2023Article
- In vitro naphthylquinoxaline thymidine conjugate and UVA treated cancer cells are effective therapeutic vaccines for tumors in vivo with CpG as the adjuvant.Journal of advanced research · 2022Article
- Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression.Cancer discovery · 2021Article
- Article
- Modeling the tumor immune microenvironment for drug discovery using 3D culture.APL bioengineering · 2021Article
- Melanoma-associated fibroblasts impair CD8+ T cell function and modify expression of immune checkpoint regulators via increased arginase activity.Cellular and molecular life sciences : CMLS · 2021Article
- Co-culture Systems of Drug-Treated Acute Myeloid Leukemia Cells and T Cells for In Vitro and In Vivo Study.STAR protocols · 2020Article
- Real time visualization of cancer cell death, survival and proliferation using fluorochrome-transfected cells in an IncuCyteJournal of biological methods · 2020Article
- Anticancer Effect ofFrontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.